BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30267626)

  • 1. A pilot plasma-ctDNA ring trial for the Cobas® EGFR Mutation Test in clinical diagnostic laboratories.
    Ntzifa A; Kroupis C; Haliassos A; Lianidou E
    Clin Chem Lab Med; 2019 Apr; 57(5):e97-e101. PubMed ID: 30267626
    [No Abstract]   [Full Text] [Related]  

  • 2. Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic.
    Linda Č; Markéta K; Ivana T; Eva P; Milada M; Hana V; Ondřej H; Karolína B; Jiří D; Monika B; Pavel D
    Klin Onkol; 2018; 31(5):353-360. PubMed ID: 30541321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 4. Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis.
    Passiglia F; Rizzo S; Rolfo C; Galvano A; Bronte E; Incorvaia L; Listi A; Barraco N; Castiglia M; Calo V; Bazan V; Russo A
    Curr Cancer Drug Targets; 2018; 18(7):697-705. PubMed ID: 29521235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA testing in advanced non-small cell lung cancer.
    Moding EJ; Diehn M; Wakelee HA
    Lung Cancer; 2018 May; 119():42-47. PubMed ID: 29656751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.
    Arriola E; Paredes-Lario A; García-Gomez R; Diz-Tain P; Constenla M; García-Girón C; Márquez G; Reck M; López-Vivanco G
    Clin Transl Oncol; 2018 Oct; 20(10):1261-1267. PubMed ID: 29623586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays.
    Jiang XW; Liu W; Zhu XY; Xu XX
    Mol Med Rep; 2019 Jul; 20(1):593-603. PubMed ID: 31115577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium.
    van der Leest P; Rozendal P; Hinrichs J; van Noesel CJM; Zwaenepoel K; Deiman B; Huijsmans CJJ; van Eijk R; Speel EJM; van Haastert RJ; Ligtenberg MJL; van Schaik RHN; Jansen MPHM; Dubbink HJ; de Leng WW; Leers MPG; Tamminga M; van den Broek D; van Kempen LC; Schuuring E
    Clin Chem; 2024 May; 70(5):759-767. PubMed ID: 38484302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.
    Fassunke J; Ihle MA; Lenze D; Lehmann A; Hummel M; Vollbrecht C; Penzel R; Volckmar AL; Stenzinger A; Endris V; Jung A; Lehmann U; Zeugner S; Baretton G; Kreipe H; Schirmacher P; Kirchner T; Dietel M; Büttner R; Merkelbach-Bruse S
    Virchows Arch; 2017 Oct; 471(4):509-520. PubMed ID: 28884371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients.
    Zhang H; He B; Cui J; Zhao M; Zhang Z
    Cancer Biomark; 2018; 23(3):427-436. PubMed ID: 30223392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA.
    Keppens C; Dequeker EMC; Patton SJ; Normanno N; Fenizia F; Butler R; Cheetham M; Fairley JA; Williams H; Hall JA; Schuuring E; Deans ZC;
    BMC Cancer; 2018 Aug; 18(1):804. PubMed ID: 30092778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Fan G; Zhang K; Ding J; Li J
    Oncotarget; 2017 May; 8(20):33922-33932. PubMed ID: 28430611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [NON-INVASIVE MONITORING OF EGFR MUTATIONS IN NONSMALL CELL LUNG CANCER (NSCLC) DURING TARGETED THERAPY: STATE OF THE ART AND OUR EXPERIENCE].
    Chermenko PA; Zaretsky AR; Shagin DA; Breder VV; Laktionov KK
    Vopr Onkol; 2016; 62(4):513-8. PubMed ID: 30475540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
    Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J
    Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour DNA in
    Cabanero M; Tsao MS
    Curr Oncol; 2018 Jun; 25(Suppl 1):S38-S44. PubMed ID: 29910646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.
    Dono M; De Luca G; Lastraioli S; Anselmi G; Dal Bello MG; Coco S; Vanni I; Grossi F; Vigani A; Genova C; Ferrarini M; Ravetti JL; Zupo S
    Mol Med; 2019 Apr; 25(1):15. PubMed ID: 31029076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasensitive and quantitative detection of EGFR mutations in plasma samples from patients with non-small-cell lung cancer using a dual PNA clamping-mediated LNA-PNA PCR clamp.
    Zhang S; Chen Z; Huang C; Ding C; Li C; Chen J; Zhao J; Miao L
    Analyst; 2019 Feb; 144(5):1718-1724. PubMed ID: 30663747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe.
    Keppens C; Palma JF; Das PM; Scudder S; Wen W; Normanno N; van Krieken JH; Sacco A; Fenizia F; Gonzalez de Castro D; Hönigschnabl S; Kern I; Lopez-Rios F; Lozano MD; Marchetti A; Halfon P; Schuuring E; Setinek U; Sorensen B; Taniere P; Tiemann M; Vosmikova H; Dequeker EMC
    J Mol Diagn; 2018 Jul; 20(4):483-494. PubMed ID: 29704571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer.
    Wei Z; Wang W; Shu Z; Zhou X; Zhang Y
    Med Sci Monit; 2017 Jul; 23():3627-3634. PubMed ID: 28742791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.
    Zhou Y; Ma Y; Shi H; Du Y; Huang Y
    Sci Rep; 2018 Oct; 8(1):15426. PubMed ID: 30337598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.